secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0001819790-24-000050
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus secures $200M non-dilutive credit facility from Pharmakon; draws $75M initially
--------------------------------------------------------------------------------

- Initial $75M drawn April 19, 2024; used to repay Hercules Capital/SVB debt and for corporate purposes.
- Additional $125M available in three tranches ($25M, $50M, $50M) through Dec 2025, subject to revenue milestones.
- Interest at SOFR + 6.75% (3.75% floor); five-year interest-only, matures April 19, 2029.
- No warrants or financial covenants; loan secured by substantially all assets.
- Net proceeds ~$40M after repayment and fees; total committed capital from Pharmakon $200M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000050/0001819790-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000050/tars-20240419.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer